FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119228723> ?p ?o ?g. }

• W3119228723 endingPage "1447" @default.
• W3119228723 startingPage "1437" @default.
• W3119228723 abstract "AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL).AALL0932 enrolled 9,229 patients with B-ALL; 2,364 average-risk (AR) patients were randomly assigned (2 × 2 factorial design) at the start of maintenance therapy to vincristine/dexamethasone pulses every 4 (VCR/DEX4) or every 12 (VCR/DEX12) weeks, and a starting dose of weekly oral methotrexate of 20 mg/m2 (MTX20) or 40 mg/m2 (MTX40).Five-year event-free survival and overall survival (OS) from enrollment (with 95% CIs), for all eligible and evaluable SR B-ALL patients (n = 9,226), were 92.0% (91.1% and 92.8%) and 96.8% (96.2% and 97.3%), respectively. The 5-year DFS and OS from the start of maintenance for randomly assigned AR patients were 94.6% (93.3% and 95.9%) and 98.5% (97.7% and 99.2%), respectively. The 5-year DFS and OS for patients randomly assigned to receive VCR/DEX4 (n = 1,186) versus VCR/DEX12 (n = 1,178) were 94.1% (92.2% and 96.0%) and 98.3% (97.2% and 99.4%) v 95.1% (93.3% and 96.9%) and 98.6% (97.7% and 99.6%), respectively (P = .86 and .69). The 5-year DFS and OS for AR patients randomly assigned to receive MTX20 versus MTX40 were 95.1% (93.3% and 96.8%) and 98.8% (97.9% and 99.7%) v 94.2% (92.2% and 96.1%) and 98.1% (97.0% and 99.2%), respectively (P = .92 and .89).The 0NCI-SR AR B-ALL who received VCR/DEX12 had outstanding outcomes despite receiving one third of the vincristine/dexamethasone pulses previously used as standard of care on Children's Oncology Group (COG) trials. The higher starting dose of MTX of 40 mg/m2/week did not improve outcomes when compared with 20 mg/m2/week. The decreased frequency of vincristine/dexamethasone pulses has been incorporated into frontline COG B-ALL trials to decrease the burden of therapy for patients and their families." @default.
• W3119228723 created "2021-01-18" @default.
• W3119228723 creator A5006250220 @default.
• W3119228723 creator A5009866488 @default.
• W3119228723 creator A5010578315 @default.
• W3119228723 creator A5010840699 @default.
• W3119228723 creator A5013754928 @default.
• W3119228723 creator A5013922885 @default.
• W3119228723 creator A5021059238 @default.
• W3119228723 creator A5022541563 @default.
• W3119228723 creator A5023214494 @default.
• W3119228723 creator A5024573751 @default.
• W3119228723 creator A5025004880 @default.
• W3119228723 creator A5031246149 @default.
• W3119228723 creator A5033126546 @default.
• W3119228723 creator A5056916024 @default.
• W3119228723 creator A5060686708 @default.
• W3119228723 creator A5072352456 @default.
• W3119228723 creator A5074089943 @default.
• W3119228723 creator A5079420293 @default.
• W3119228723 creator A5080485119 @default.
• W3119228723 creator A5085010022 @default.
• W3119228723 creator A5087827217 @default.
• W3119228723 date "2021-05-01" @default.
• W3119228723 modified "2023-10-11" @default.
• W3119228723 title "Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932" @default.
• W3119228723 cites W1256525631 @default.
• W3119228723 cites W170801347 @default.
• W3119228723 cites W1909437603 @default.
• W3119228723 cites W1939017986 @default.
• W3119228723 cites W1971211622 @default.
• W3119228723 cites W197329508 @default.
• W3119228723 cites W1975434568 @default.
• W3119228723 cites W1990486388 @default.
• W3119228723 cites W1992131964 @default.
• W3119228723 cites W2008735086 @default.
• W3119228723 cites W2010881564 @default.
• W3119228723 cites W2012218714 @default.
• W3119228723 cites W2025900968 @default.
• W3119228723 cites W2029067186 @default.
• W3119228723 cites W2033345378 @default.
• W3119228723 cites W2038252730 @default.
• W3119228723 cites W2044141667 @default.
• W3119228723 cites W2059999488 @default.
• W3119228723 cites W2067159263 @default.
• W3119228723 cites W2068155954 @default.
• W3119228723 cites W2070781226 @default.
• W3119228723 cites W2075139424 @default.
• W3119228723 cites W2078388765 @default.
• W3119228723 cites W2085665378 @default.
• W3119228723 cites W2096966147 @default.
• W3119228723 cites W2098908574 @default.
• W3119228723 cites W2119685895 @default.
• W3119228723 cites W2134118606 @default.
• W3119228723 cites W2141612177 @default.
• W3119228723 cites W2157249349 @default.
• W3119228723 cites W2157627970 @default.
• W3119228723 cites W2169291909 @default.
• W3119228723 cites W2173315827 @default.
• W3119228723 cites W2267320788 @default.
• W3119228723 cites W2314280557 @default.
• W3119228723 cites W2319067349 @default.
• W3119228723 cites W2333162224 @default.
• W3119228723 cites W2336649003 @default.
• W3119228723 cites W2528140859 @default.
• W3119228723 cites W2593461816 @default.
• W3119228723 cites W2767293858 @default.
• W3119228723 cites W2944332773 @default.
• W3119228723 cites W4293241248 @default.
• W3119228723 cites W70913691 @default.
• W3119228723 doi "https://doi.org/10.1200/jco.20.00494" @default.
• W3119228723 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8274746" @default.
• W3119228723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33411585" @default.
• W3119228723 hasPublicationYear "2021" @default.
• W3119228723 type Work @default.
• W3119228723 sameAs 3119228723 @default.
• W3119228723 citedByCount "40" @default.
• W3119228723 countsByYear W31192287232021 @default.
• W3119228723 countsByYear W31192287232022 @default.
• W3119228723 countsByYear W31192287232023 @default.
• W3119228723 crossrefType "journal-article" @default.
• W3119228723 hasAuthorship W3119228723A5006250220 @default.
• W3119228723 hasAuthorship W3119228723A5009866488 @default.
• W3119228723 hasAuthorship W3119228723A5010578315 @default.
• W3119228723 hasAuthorship W3119228723A5010840699 @default.
• W3119228723 hasAuthorship W3119228723A5013754928 @default.
• W3119228723 hasAuthorship W3119228723A5013922885 @default.
• W3119228723 hasAuthorship W3119228723A5021059238 @default.
• W3119228723 hasAuthorship W3119228723A5022541563 @default.
• W3119228723 hasAuthorship W3119228723A5023214494 @default.
• W3119228723 hasAuthorship W3119228723A5024573751 @default.
• W3119228723 hasAuthorship W3119228723A5025004880 @default.
• W3119228723 hasAuthorship W3119228723A5031246149 @default.
• W3119228723 hasAuthorship W3119228723A5033126546 @default.
• W3119228723 hasAuthorship W3119228723A5056916024 @default.
• W3119228723 hasAuthorship W3119228723A5060686708 @default.
• W3119228723 hasAuthorship W3119228723A5072352456 @default.
• W3119228723 hasAuthorship W3119228723A5074089943 @default.

• next